PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: PR Newswire
SOUTH PLAINFIELD, N.J., Jan. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today launched PRIORITY, an annual funding program for innovative research. In its inaugural year, PRIORITY will fund programs designed to improve Duchenne screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease. "As a research-driven, patient-centric company, it's important to PTC that we support the efforts of clinicians and researchers who share our passion for improving the clinical care of people with rare, genetic disorders," said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics. "Our hope is that each year, the PRIORITY program will help accelerate research into innovative, practicable, and sustainable solutions to the many challenges posed by these disorders. In 2019, we are excited to be creating opportunities for improved screening and diagnosis of Duchenne to ensure patients can receive the best care as early a
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827 [Seeking Alpha]Seeking Alpha
- Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792 [Seeking Alpha]Seeking Alpha
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- PTC Therapeutics (NASDAQ:PTCT) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating.MarketBeat
PTCT
Earnings
- 11/4/25 - Beat
PTCT
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form SCHEDULE
- 12/3/25 - Form 4
- PTCT's page on the SEC website